The Lynx Group

Emerging Therapies

Patients with previously treated metastatic urothelial cancer had response rates that exceeded historical standards when treated with an investigational immunotherapeutic agent, updated results of a large phase 2 clinical trial showed. Treatment with the PD-1 ligand 1 (PD-L1) inhibitor atezolizumab led to an overall response rate of 15% in 311 patients, including a 26% rate among patients who had the highest levels of PD-L1 expression. Historical data have demonstrated response rates of about 10% for second-line therapy and beyond.
Read Article

Barcelona, Spain—Locoregional therapies for hepatocellular carcinoma and for colorectal cancer (CRC) metastases to the liver continue to demonstrate promising outcomes in clinical trials, according to findings presented at the 2015 European Society for Medical Oncology World Congress on Gastrointestinal Cancer.
Read Article

Vienna, Austria—Patients with advanced, pretreated renal-cell carcinoma (RCC) who have limited treatment options got good news from 2 important practice-changing trials, CheckMate 025 and METEOR, which were presented as late-breaking abstracts at the 2015 European Cancer Congress (ECC). CheckMate 025 showed a survival benefit for nivolumab (Opdivo) over standard therapy with everolimus (Afinitor) in patients with previously treated advanced RCC. This is the first trial to show a survival benefit for an immune checkpoint inhibitor after standard therapy has failed. METEOR showed that cabozantinib (Cometriq) nearly doubled progression-free survival (PFS) compared with standard everolimus in patients with advanced RCC whose disease progressed with previous vascular endothelial growth factor (VEGF) receptor (VEGFR)-targeted therapy.
Read Article

“Everolimus is the first targeted agent to show robust antitumor activity with acceptable tolerability across a broad spectrum of NETs,” said James C. Yao, MD.
Read Article

The treatment of patients with colorectal cancer (CRC) may benefit from immunotherapy with anti–PD-1 agents, based on results of a recent study using pembrolizumab (Keytruda).
Read Article

Copenhagen, Denmark—Biosimilar filgrastim (Nivestim; Hospira), which was approved earlier this year by the European Commission but not yet by the FDA, showed effectiveness for the treatment of neutropenia and febrile neutropenia (FN) in patients undergoing cytotoxic chemotherapy for solid tumors and hematologic malignancies, according to a study presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology meeting.
Read Article

Vienna, Austria—Immunotherapy is poised to become a game changer for patients with non–small-cell lung cancer (NSCLC).
Read Article

Boston, MA—Rociletinib, a specially engineered third-generation EGFR inhibitor, is accumulating an impressive track record in early studies of non–small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the T790M mutation, a heretofore patient population with unmet needs. T790M, the most common mutation associated with resistance to first-line EGFR-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs.
Read Article

Clinicians will soon have more targeted therapies at their disposal, including drugs with novel mechanisms of action.
Read Article

A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study appeared online July 20, 2015, in Nature Medicine.
Read Article

Page 5 of 6

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: